Last 48 quarters of trend data · Consumer Defensive · Packaged Foods
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.89 | — | — | 10.30 | — | — | 14.97 | 14.17 | 39.01 | 16.93 | 20.94 | 14.10 | 15.40 | 24.83 | 17.71 | 16.55 | 20.15 | 17.96 | 18.75 | 17.25 | 24.56 |
| — | — | — | -27.3% | — | — | -28.5% | +0.5% | +153.3% | -31.8% | +18.3% | -14.8% | -23.6% | +38.2% | -5.6% | -4.0% | -18.0% | +4.4% | +37.3% | +0.9% | +138.3% | |
| P/S Ratio | 0.28 | 0.33 | 0.45 | 0.31 | 0.39 | 0.61 | 0.61 | 0.53 | 0.80 | 0.90 | 1.02 | 1.03 | 1.17 | 1.33 | 1.29 | 1.22 | 1.12 | 1.16 | 1.36 | 1.42 | 1.86 |
| — | -45.5% | -27.2% | -41.5% | -51.0% | -32.4% | -39.9% | -48.3% | -31.2% | -32.1% | -20.8% | -16.0% | +3.8% | +15.0% | -5.8% | -13.6% | -39.6% | -32.7% | -12.0% | -16.6% | +41.6% | |
| P/B Ratio | 0.43 | 0.48 | 0.70 | 0.52 | 0.61 | 0.90 | 0.99 | 0.91 | 1.17 | 1.36 | 1.69 | 1.87 | 2.08 | 2.41 | 2.61 | 2.67 | 2.36 | 2.62 | 3.58 | 3.96 | 5.04 |
| — | -46.4% | -29.3% | -42.4% | -48.1% | -33.9% | -41.8% | -51.5% | -43.7% | -43.8% | -35.2% | -29.9% | -12.0% | -8.0% | -26.9% | -32.6% | -53.2% | -44.5% | -28.3% | -23.7% | +36.2% | |
| P/FCF | 29.52 | — | 4.93 | 10.93 | — | — | 20.06 | 10.45 | 43.04 | 6.67 | 40.74 | 16.16 | 13.80 | 13.66 | 51.53 | 28.34 | 6.89 | 10.56 | 28.04 | 21.57 | 22.86 |
| — | — | -75.4% | +4.6% | — | — | -50.8% | -35.3% | +211.9% | -51.2% | -20.9% | -43.0% | +100.2% | +29.3% | +83.7% | +31.4% | -69.9% | -30.5% | +102.0% | -25.5% | +159.9% | |
| EV / EBITDA | 2.43 | 6.32 | — | 1.72 | 1.92 | 8.72 | 4.04 | 3.60 | 9.63 | 4.24 | 5.67 | 5.12 | 6.14 | 9.10 | 7.82 | 7.17 | 6.75 | 7.42 | 8.79 | 8.52 | 11.90 |
| — | -27.5% | — | -52.4% | -80.1% | +105.8% | -28.7% | -29.6% | +56.8% | -53.4% | -27.5% | -28.7% | -8.9% | +22.7% | -11.0% | -15.8% | -43.3% | -16.2% | +14.4% | -7.7% | +105.8% | |
| EV / EBIT | 2.11 | — | — | 2.59 | 12.29 | 51.08 | 5.58 | 5.45 | 12.86 | 4.81 | 6.60 | 5.61 | 6.68 | 10.07 | 8.61 | 8.06 | 8.21 | 8.95 | 10.31 | 9.89 | 13.96 |
| — | — | — | -52.5% | -4.4% | +962.6% | -15.4% | -2.9% | +92.6% | -52.2% | -23.4% | -30.5% | -18.7% | +12.5% | -16.5% | -18.4% | -41.2% | -11.8% | +23.0% | -4.4% | +122.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 76.3% | 78.3% | 76.2% | 78.2% | 77.2% | 75.4% | 75.6% | 80.1% | 78.6% | 79.3% | 79.7% | 79.5% | 78.5% | 80.5% | 79.1% | 78.2% | 78.6% | 80.0% | 80.0% | 79.1% |
| — | -1.1% | +3.9% | +0.8% | -2.4% | -1.9% | -4.8% | -5.1% | +0.7% | +0.1% | -1.5% | +0.7% | +1.7% | -0.0% | +0.6% | -1.0% | -1.2% | -2.2% | -2.5% | -0.3% | -1.0% | |
| Operating Margin | 5.5% | -0.7% | -9.0% | 5.5% | 7.6% | 0.6% | 7.1% | 6.3% | 3.8% | 7.8% | 8.4% | 10.8% | 11.0% | 8.3% | 10.2% | 10.8% | 9.9% | 9.7% | 11.1% | 12.1% | 11.8% |
| — | -222.8% | -226.3% | -11.7% | +98.4% | -92.6% | -15.4% | -42.0% | -64.9% | -5.6% | -18.2% | +0.2% | +10.7% | -14.9% | -7.7% | -10.8% | -16.1% | -34.7% | -30.4% | -15.6% | -30.3% | |
| Net Margin | 1.2% | -2.7% | -9.6% | 3.0% | -0.8% | -3.1% | 4.1% | 3.8% | 2.1% | 5.3% | 4.9% | 7.3% | 7.6% | 5.3% | 7.3% | 7.4% | 5.6% | 6.4% | 7.2% | 8.2% | 7.6% |
| — | +11.6% | -333.9% | -20.3% | -137.4% | -157.6% | -16.5% | -48.1% | -72.3% | -0.4% | -32.5% | -1.9% | +35.1% | -16.9% | +0.2% | -10.1% | -26.2% | -35.8% | -36.2% | -17.2% | -40.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.8% | -1.0% | -3.7% | 1.3% | -0.3% | -1.1% | 1.7% | 1.6% | 0.8% | 2.0% | 2.1% | 3.3% | 3.5% | 2.4% | 3.7% | 4.1% | 3.0% | 3.7% | 4.8% | 5.7% | 5.1% |
| — | +12.9% | -322.2% | -20.8% | -137.9% | -155.1% | -19.9% | -51.6% | -76.9% | -16.0% | -44.9% | -19.7% | +14.5% | -34.1% | -22.5% | -27.8% | -40.9% | -45.2% | -48.1% | -21.1% | -46.4% | |
| ROA | 1.4% | -0.8% | -3.0% | 1.0% | -0.2% | -0.9% | 1.3% | 1.3% | 0.6% | 1.6% | 1.7% | 2.6% | 2.7% | 1.9% | 2.9% | 3.1% | 2.2% | 2.7% | 3.4% | 3.9% | 3.5% |
| — | +11.8% | -327.4% | -19.4% | -138.2% | -154.8% | -21.2% | -52.0% | -76.8% | -13.6% | -42.2% | -14.3% | +22.4% | -29.7% | -15.5% | -21.7% | -36.8% | -42.6% | -47.9% | -21.9% | -46.0% | |
| ROIC | 8.6% | -0.3% | -3.5% | 2.3% | 2.9% | 0.2% | 2.9% | 2.7% | 2.0% | 6.7% | 7.6% | 10.5% | 10.6% | 8.0% | 11.1% | 12.6% | 10.4% | 10.1% | 13.1% | 14.8% | 14.6% |
| — | -229.8% | -221.4% | -13.2% | +46.4% | -96.9% | -61.6% | -74.3% | -81.0% | -15.5% | -31.9% | -16.7% | +1.4% | -20.9% | -15.1% | -15.0% | -28.7% | -50.1% | -51.3% | -33.8% | -51.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | — | — | 0.02 | 0.02 | — | — | 0.04 | 0.07 | — | — | 0.00 | 0.03 | — | — | — | 0.03 | — | — | 0.03 | 0.04 |
| — | — | — | -40.2% | -64.3% | — | — | +1392.1% | +151.8% | — | — | — | -16.3% | — | — | — | -27.5% | — | — | — | -10.0% | |
| Debt / EBITDA | 0.15 | — | — | 0.59 | 0.51 | — | — | 0.89 | 2.78 | — | — | 0.04 | 0.45 | — | — | — | 0.50 | — | — | 0.26 | 0.47 |
| — | — | — | -33.3% | -81.7% | — | — | +1900.7% | +512.8% | — | — | — | -8.4% | — | — | — | +6.5% | — | — | — | +25.8% | |
| Current Ratio | 2.24 | 2.59 | 2.66 | 2.51 | 2.24 | 2.23 | 2.15 | 2.05 | 2.00 | 3.93 | 4.03 | 3.74 | 3.52 | 3.47 | 3.41 | 3.04 | 2.65 | 2.71 | 2.56 | 2.30 | 2.26 |
| — | +16.2% | +23.5% | +22.5% | +12.2% | -43.4% | -46.6% | -45.2% | -43.1% | +13.3% | +18.5% | +23.0% | +32.6% | +28.0% | +33.0% | +32.0% | +17.5% | +16.2% | +2.7% | -6.5% | -10.4% | |
| Quick Ratio | 1.45 | 1.84 | 1.84 | 1.69 | 1.45 | 1.46 | 1.47 | 1.51 | 1.50 | 3.37 | 3.44 | 3.20 | 3.00 | 2.94 | 2.86 | 2.54 | 2.18 | 2.18 | 1.93 | 1.69 | 1.65 |
| — | +25.8% | +25.5% | +11.6% | -3.7% | -56.7% | -57.3% | -52.7% | -50.0% | +14.9% | +20.2% | +25.7% | +37.3% | +34.9% | +48.2% | +51.0% | +32.8% | +26.3% | +1.2% | -10.6% | -17.0% | |
| Interest Coverage | 50.32 | -20.16 | — | 65.44 | 34.96 | 37.61 | 73.65 | 41.73 | 81.84 | 380.76 | 397.14 | 522.37 | 184.52 | 478.47 | 624.49 | 920.39 | 713.56 | 726.75 | 306.29 | 1041.22 | 1759.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying USNA stock.
USANA Health Sciences, Inc.'s current P/E is -11.9x. The average P/E over the last 1 quarters is 10.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
USANA Health Sciences, Inc.'s current operating margin is 5.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking USANA Health Sciences, Inc.'s business trajectory between earnings reports.